Jump to content
  • rrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

All Activity

This stream auto-updates

  1. Today
  2. Yesterday
  3. J Dermatolog Treat. 2021 Jul 22:1-8. doi: 10.1080/09546634.2021.1959507. Online ahead of print. NO ABSTRACT PMID:34291712 | DOI:10.1080/09546634.2021.1959507 {url} = URL to article
  4. Front Immunol. 2021 Jul 5;12:674871. doi: 10.3389/fimmu.2021.674871. eCollection 2021. ABSTRACT Rosacea is a common chronic inflammatory condition that mainly affects the central face. However, the molecular background of the normal central face and the transcriptional profiling and immune cell composition of rosacea lesions remain largely unknown. Here, we performed whole-skin and epidermal RNA-seq of central facial skin from healthy individuals, lesions and matched normal skin from rosacea patients. From whole-skin RNA-seq, the site-specific gene signatures for central facial skin were mainly enriched in epithelial cell differentiation, with upregulation of the activator protein-1 (AP1) transcription factor (TF). We identified the common upregulated inflammatory signatures and diminished keratinization signature for rosacea lesions. Gene ontology, pathway, TF enrichment and immunohistochemistry results suggested that STAT1 was the potential core of the critical TF networks connecting the epithelial-immune crosstalk in rosacea lesions. Epidermal RNA-seq and immunohistochemistry analysis further validated the epithelial-derived STAT1 signature in rosacea lesions. The epidermal STAT1/IRF1 signature was observed across ETR, PPR, and PhR subtypes. Immune cell composition revealed that macrophages were common in all 3 subtypes. Finally, we described subtype-specific gene signatures and immune cell composition correlated with phenotypes. These findings reveal the specific epithelial differentiation in normal central facial skin, and epithelial-immune crosstalk in lesions providing insight into an initial keratinocyte pattern in the pathogenesis of rosacea. PMID:34290700 | PMC:PMC8287635 | DOI:10.3389/fimmu.2021.674871 {url} = URL to article
  5. Last week
  6. Med Res Rev. 2021 Jul 21. doi: 10.1002/med.21842. Online ahead of print. ABSTRACT The sesquiterpene lactone artemisinin from Artemisia annua L. is well established for malaria therapy, but its bioactivity spectrum is much broader. In this review, we give a comprehensive and timely overview of the literature regarding the immunosuppressive activity of artemisinin-type compounds toward inflammatory and autoimmune diseases. Numerous receptor-coupled signaling pathways are inhibited by artemisinins, including the receptors for interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), β3-integrin, or RANKL, toll-like receptors and growth factor receptors. Among the receptor-coupled signal transducers are extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), AKT serine/threonine kinase (AKT), mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK) kinase (MEK), phospholipase C γ1 (PLCγ), and others. All these receptors and signal transduction molecules are known to contribute to the inhibition of the transcription factor nuclear factor κ B (NF-κB). Artemisinins may inhibit NF-κB by silencing these upstream pathways and/or by direct binding to NF-κB. Numerous NF-κB-regulated downstream genes are downregulated by artemisinin and its derivatives, for example, cytokines, chemokines, and immune receptors, which regulate immune cell differentiation, apoptosis genes, proliferation-regulating genes, signal transducers, and genes involved in antioxidant stress response. In addition to the prominent role of NF-κB, other transcription factors are also inhibited by artemisinins (mammalian target of rapamycin [mTOR], activating protein 1 [AP1]/FBJ murine osteosarcoma viral oncogene homologue [FOS]/JUN oncogenic transcription factor [JUN]), hypoxia-induced factor 1α (HIF-1α), nuclear factor of activated T cells c1 (NF-ATC1), Signal transducers and activators of transcription (STAT), NF E2-related factor-2 (NRF-2), retinoic-acid-receptor-related orphan nuclear receptor γ (ROR-γt), and forkhead box P-3 (FOXP-3). Many in vivo experiments in disease-relevant animal models demonstrate therapeutic efficacy of artemisinin-type drugs against rheumatic diseases (rheumatoid arthritis, osteoarthritis, lupus erythematosus, arthrosis, and gout), lung diseases (asthma, acute lung injury, and pulmonary fibrosis), neurological diseases (autoimmune encephalitis, Alzheimer's disease, and myasthenia gravis), skin diseases (dermatitis, rosacea, and psoriasis), inflammatory bowel disease, and other inflammatory and autoimmune diseases. Randomized clinical trials should be conducted in the future to translate the plethora of preclinical results into clinical practice. PMID:34288018 | DOI:10.1002/med.21842 {url} = URL to article
  7. An Bras Dermatol. 2021 Jul 15:S0365-0596(21)00173-2. doi: 10.1016/j.abd.2021.02.004. Online ahead of print. ABSTRACT BACKGROUND: The frequency of autoimmune diseases and thyroid cancer has been increasingly reported in association with rosacea. However, studies investigating thyroid diseases in rosacea are scarce with conflicting results. OBJECTIVE: To investigate the relationship between thyroid disorders and rosacea. METHODS: A large case-control study on age- and gender-matched 2091 rosacea patients and 9572 controls was conducted. Rosacea patients using the rosacea-specific ICD codes were compiled from the hospital records. Additionally, all participants were evaluated in terms of the presence of hypothyroidism and hyperthyroidism. Conditional logistic regression analysis was used to compute case-control odds ratios (OR) with 95% confidence intervals. RESULTS: The analysis comprehended 2091 rosacea patients (1546 female, 545 male; mean 48.73 ± 14.53 years) and 9572 controls (7009 female, 2563 male; mean 48.73 ± 15.1 years). Whereas the rate of hypothyroidism was significantly higher in rosacea patients (OR = 1.3, 95% CI 1.13-1.49, p < 0.001), there was no significant difference in the rate of hyperthyroidism between the groups (OR = 1.12, 95% CI 0.81-1.53, p = 0.497). Stratification for genderrevealed a significant association between hypothyroidism and rosacea in females (OR = 1.27, 95% CI 1.1-1.47, p = 0.002) and males (OR = 1.58, 95% CI 1.04-2.4, p = 0.032). The frequency of hypothyroidism in rosacea patients increased towards the age range of 40-49 and then decreased, parallel with the hypothyroidism frequency of the study population. STUDY LIMITATIONS: Different subtypes and severities of rosacea were not distinguished. CONCLUSIONS: Hypothyroidism may be a comorbidity of rosacea and investigation for hypothyroidism may be appropriate when evaluating rosacea patients. PMID:34275693 | DOI:10.1016/j.abd.2021.02.004 {url} = URL to article
  8. Clin Cosmet Investig Dermatol. 2021 Jul 6;14:779-814. doi: 10.2147/CCID.S315711. eCollection 2021. ABSTRACT Dermal filler treatments require constant reassessment for improving and safeguarding the rapidly evolving aesthetic field. Suboptimal injection technique, patient selection and product knowledge have touted a concerning increase in filler complications, with new challenges such as the COVID-19 pandemic leading to new paradigms in the understanding, prevention, diagnosis and treatment of complications. The updated 10-point plan has been developed to curtail complications through consideration of causative factors, categorized as patient, product, and procedure-related. Patient-related factors include a preprocedural consultation with careful elucidation of skin conditions (acne, rosacea, dermatitis), systemic disease (allergies, autoimmune disease, underlying bacterial and viral disease (herpes simplex virus, COVID-19 infection), medications (antineoplastic drugs, recreational drugs) and previous cosmetic procedures (including fillers and energy-based devices). Patient assessment should include standardized photography and also evaluate the role of social media, ethnicity, gender, generational, and LGBTQ+ needs. Specified informed consent for both adverse events and their treatment is essential due to the increase in vascular complications, including the risk of blindness. Product-related factors include the powerful advantage of reversibility when using hyaluronic acid (HA) products. Product characteristics such as molecular weight and filler degradation should be understood. Product layering over late or minimally degradable fillers is still inadvisable due to the initial filler being teased into reactivity. Procedural factors such as consistent photographic documentation, procedural planning, aseptic non-touch technique (ANTT), knowledge of topographical anatomy and angiosomes, and technical dexterity including pinch anatomy and needle skills are of pivotal importance. The final section is dedicated to algorithms and checklists for managing and treating complications such as allergic hypersensitivity reactions, vascular events, infection, edema and late-onset adverse events (LOAEs). The updated 10-point plan is a methodical strategy aimed at further minimising the risk of dermal filler complications. PMID:34276222 | PMC:PMC8279269 | DOI:10.2147/CCID.S315711 {url} = URL to article
  9. J Am Acad Dermatol. 2021 Jul 10:S0190-9622(21)02012-0. doi: 10.1016/j.jaad.2021.06.865. Online ahead of print. NO ABSTRACT PMID:34274412 | DOI:10.1016/j.jaad.2021.06.865 {url} = URL to article
  10. The RRDi is pleased to announce a new page, Rosacea Episodes.
  11. Earlier
  12. J Craniofac Surg. 2021 Jul 15. doi: 10.1097/SCS.0000000000007963. Online ahead of print. ABSTRACT BACKGROUND: Rhinophyma is the severe rosacea whit hypertrophy of sebaceous glands in nasal tissue, which severely influences the patient's appearance. Surgical therapy is the best method for treating moderate-to-severe rhinophyma. In this study, we used a new ameliorated scarification for 30 patients with moderate-to-severe rhinophyma. OBJECTIVE: To observe the effect of five-blades scratcher surgery on moderate-to severe rhinophyma between 2016 and 2019 in our center. MATERIALS AND METHODS: A total of 30 patients were treated with five-blades scratcher under tumescent anesthesia. Outcomes were determined by a patient questionnaire. RESULTS: Of 30 patients, all of them answered the questionnaire and were included in this study with a follow-up time of 12 months. Cosmetic results were evaluated as very good or good in 90% of patients. The majority of patients (87%) were very satisfied or satisfied with the postoperative result. Surgical treatment of rhinophyma improved patients' quality of life in 67% of patients. Recurrence of rhinophyma was detected in 7% of patients. In all, 100% of the patients stated that they would recommend this treatment to others. CONCLUSIONS: Five-blades scratcher is an effective therapy for rhinophyma with excellent outcome. PMID:34267144 | DOI:10.1097/SCS.0000000000007963 {url} = URL to article
  13. J Neuroophthalmol. 2021 Jul 13. doi: 10.1097/WNO.0000000000001290. Online ahead of print. NO ABSTRACT PMID:34270518 | DOI:10.1097/WNO.0000000000001290 {url} = URL to article
  14. Br J Dermatol. 2021 Jul 16. doi: 10.1111/bjd.20645. Online ahead of print. ABSTRACT antibiotics represent the first-line hidradenitis suppurativa (HS) treatment, although HS is not an infectious disease1 . Prolonged antibiotic courses exhibit an anti-inflammatory effect, utilized for treating follicular/inflammatory skin diseases, e.g. acne and rosacea. Clindamycin/rifampicin or tetracyclines are usually administered for 10 to 12 weeks in moderate-to-severe HS treatment1 , mostly based on retrospective studies using non-validated severity scoring systems. PMID:34270785 | DOI:10.1111/bjd.20645 {url} = URL to article
  15. You may be having issues trying to navigate our website using a mobile device so here is a helpful tutorial to find Rosacea Topics. Watch Video. Step one - Finding the Menu on the Home page (iOS - hopefully Android users are similar) - Look for the three bars top right corner (click): You should then see the following menu: Just under the HOME button find the NAVIGATOR button and click on it and you should see the following menu: The first word 'Navigator' is simply the title of this menu (don't click on it). The menu choices are now shown below this word, 'Navigator,' and you should begin scrolling down till you see the following: The menu button ROSACEA TOPICS is the second to the last choice. Click on ROSACEA TOPICS which brings you to the following screen: You may want to turn your mobile device horizontally to view the videos and subforums and scroll down to see all the choices: Now you can view the subforums but you are not allowed to enter a subforum without being a member of the RRDi. Membership is free and all you do register and then you can view over 7K posts and over 5.4K rosacea topics. Learn more. Hope this helps mobile device users on how to navigate our website. If you have questions, find the reply to this topic button and ask.
  16. Br J Dermatol. 2021 Jul 13. doi: 10.1111/bjd.20641. Online ahead of print. ABSTRACT Treatments for many common dermatologic diagnoses are denied insurance coverage due to their arbitrary cosmetic classification. Melasma is one such diagnosis often considered cosmetic by payers, and since it is commonly identified in darker-skinned individuals, its cosmetic classification creates an economic barrier for patients of color. Although dermatologists have previously described insurance coverage gaps for conditions typically seen in patients of color, this coverage gap has never been quantified.1 Thus, we investigated the rate of insurance coverage for first-line topical treatments for rosacea versus melasma. Rosacea and melasma share a number of key features - both are common, chronic, dermatological conditions that are exacerbated by sun exposure, are primarily treated topically, and cause measurably decreased quality of life in affected patients.2,3 Rosacea, however, is often diagnosed in patients with Fitzpatrick skin types I-II, with 91.8% of rosacea diagnoses seen in white patients, while melasma is predominantly diagnosed in patients with Fitzpatrick skin types III-V.4-6. PMID:34254297 | DOI:10.1111/bjd.20641 {url} = URL to article What is the Fitzpatrick Scale?
  17. Yes actually I went through her article on these proteins and food triggers when I read the heading I thought these natural food items are good when consumed but when I read through it I found that these compounds are found in a very trace amount naturally in these foods and do not cause any problem as such but when these chemical compounds are used as preservatives in food and personal care products, then it is of concern. Obviously we all know that preservatives are very bad for our overall health because it keeps our food fresh for a longer period of time and we can understand that what keeps our stuff fresh whether food or skin products for a longer period of time, would badly affect in a long run and when you are already immune sensitive. Eat natural as possible as you can which directly comes from nature (whether fruits or vegetables) and don't go overboard with anything. Eat less Packaged foods or remove it from your lifestyle. Understand your body and its functions. See, we take a lot of myths but what suits you, may not suit the other person when it comes to rosacea and it is all about trial and error and you need to find out what suits you best.
  18. 6554b6be8c0d829a8bf63ae0c82cf121_purchas
    Purchase. La Roche-Posay Toleriane Ultra Night Cream for Face Intense Soothing Moisturizer, Allergy Tested, 1.35 Fl oz.

    Product Description
    Amazon is an authorized retailer of La Roche-Posay products.

    This nighttime moisturizer for face is a soothing oil free, non-comedogenic night moisturizer for face specially formulated for sensitive skin. Provides immediate and long-lasting comfort for dry, uncomfortable, very sensitive skin. While you sleep, this moisturizer for face sensitive skin  helps skin defend itself against external aggressors by neutralizing free radicals on the upper layers of the skin and is gentle for sensitive skin.

    The minimalist formula has been stripped down to the essentials using carefully-selected ingredients, and is formulated without potentially-irritating ingredients such as parabens, fragrance, and drying alcohol. Air-tight packaging no outside air or contaminants get inside.

    Formulated to soothe and calm sensitive skin this face moisturizer for sensitive skin includes La Roche-Posay Thermal Spring Water, Shea Butter, Glycerin, soothing Neurosensine, and a [Carnosine/Vitamin E] antioxidant combination. This night cream sensitive skin is non-comedogenic, tested on sensitive skin and allergy-prone skin, has 0% preservatives, paraben-free, fragrance-free, drying alcohol free, lanolin-free, colorant-free.

    Ingredients: AQUA / WATER / EAU, GLYCERIN, SQUALANE, PROPANEDIOL, BUTYLENE GLYCOL, BUTYROSPERMUM PARKII BUTTER / SHEA BUTTER, PENTYLENE GLYCOL, NIACINAMIDE, DIMETHICONE, AMMONIUM POLYACRYLOYLDIMETHYL TAURATE, PO,LYMETHYLSILSESQUIOXANE, POLYSORBATE 20, TOCOPHEROL, ACETYL DIPEPTIDE-1 CETYL ESTER, ALLANTOIN, TOLUENE SULFONIC ACID, DIMETHICONOL, XANTHAN GUM, CARNOSINE, DISODIUM EDTA, CITRIC ACID, ALUMINUM STARCH OCTENYLSUCCINATE, GLYCERYL ACRYLATE/ACRYLIC ACID COPOLYMER.

    Product packaging may vary.

    $29.99 RRDi Affiliate Store
  19. 6554b6be8c0d829a8bf63ae0c82cf121_purchas
    Purchase. La Roche-Posay Anthelios Melt-In Sunscreen Milk Body & Face Sunscreen Lotion Broad Spectrum SPF 60, Oxybenzone & Octinoxate Free, Oil-Free Sunscreen

    Product Description
    Amazon is an authorized retailer of La Roche-Posay products. Anthelios 60 Body and Face Sunscreen SPF 60 Melt-In Sunscreen Milk with Antioxidants. This La Roche-Posay sunscreen’s features are: Formulated with exclusive Cell-OX Shield technology, UVA/UVB filters + Antioxidants, Broad Spectrum SPF 60 protection, Water Resistant (80 minutes), Velvety texture, easy to apply. Advanced broad spectrum sunscreen protection in a fast-absorbing, velvety texture. Tested on sensitive skin, Dermatologist tested, Oil-free, Allergy tested, Paraben-free, Fragrance-free, Non-Comedogenic A pioneer in UV protection research for over 15 years, La Roche-Posay, with Anthelios, is trusted by dermatologists worldwide for its advanced formulations in UV protection. Apply generously 15 minutes before sun exposure. Reapply sunscreen after 80 minutes of swimming or sweating, immediately after towel drying, at least every 2 hours. Children under 6 months of age: ask a doctor. ACTIVE INGREDIENTS: AVOBENZONE 3%, HOMOSALATE 10%, OCTISALATE 5%, OCTOCRYLENE 7% INACTIVE INGREDIENTS: WATER, STYRENE/ACRYLATES COPOLYMER, DIMETHICONE, POLYMETHYLSILSESQUIOXANE, BUTYLOCTYL SALICYLATE, GLYCERIN, ALCOHOL DENAT., POLY C10-30 ALKYL ACRYLATE, CAPRYLYL METHICONE, TRISILOXANE, ACRYLATES/DIMETHICONE COPOLYMER, DIETHYLHEXYL SYRINGYLIDENEMALONATE, PEG-100 STEARATE, GLYCERYL STEARATE, PHENOXYETHANOL, POTASSIUM CETYL PHOSPHATE, PROPYLENE GLYCOL, CAPRYLYL GLYCOL, PEG-8 LAURATE, ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER, TRIETHANOLAMINE, TOCOPHEROL, INULIN LAURYL CARBAMATE, DISODIUM EDTA, P-ANISIC ACID, CAPRYLIC/CAPRIC TRIGLYCERIDE, XANTHAN GUM, CASSIA ALATA LEAF EXTRACT, MALTODEXTRIN, SODIUM DODECYLBENZENESULFONATE. If wearing with makeup, apply sunscreen first, followed by makeup. Product packaging may vary.

    $21.99 RRDi Affiliate Store
  20. 6554b6be8c0d829a8bf63ae0c82cf121_purchas
    Purchase. La Roche-Posay Cicaplast Balm B5, Soothing Therapeutic Multi Purpose Cream for Dry & Irritated Skin, Body and Hand Balm, Fragrance Free. A member in the RRDi private Facebook group reports "I love the cicaplast and still do use it."

    Product Description
    Amazon is an authorized retailer of La Roche-Posay products. La Roche-Posay Cicaplast Balm B5 soothing therapeutic multi- purpose cream for Hands, Face & Body with Shea Butter is suitable for dry skin irritations for adults, children, and babies. Skin protectant cream helps protect and relieve cracked, chapped and chafed skin as well as soothe visibly irritated areas associated with dry skin. This moisturizing cream’s ultra-comforting, rich texture has non-greasy finish. Cicaplast Balm B5 is formulated with, Vitamin B5 (Panthenol) to soothe dry, rough skin, Shea Butter and Glycerin helps to nourish skin and visibly reduce the sign of irritation caused by dryness, and [Madecassoside] + [Copper - Zinc - Maganese] helps to visibly reduce the appearance of dry, irritated skin. Hydrating cream protects chafed skin due to diaper rash and helps seal out wetness, while helping to treat & prevent diaper rash. This moisturizer cream is: • Non-greasy • Paraben-free • Fragrance-free • Lanolin-free • Steroid-free • Antibiotic-free •Allergy-Tested • Tested on sensitive skin • Tested under pediatric control • Dermatologist Tested for Safety. Use this body, hands and face balm to hydrate & soothe dry areas and protect skin from drying effects of wind and cold weather. This cream also helps treat and prevent diaper rash. Apply as needed to cleansed, dry skin. Can be applied to body, face, and lips. Generous layers can be applied to overly dry areas. Avoid eye area. ACTIVE INGREDIENT: DIMETHICONE 1% INACTIVE INGREDIENTS: WATER • HYDROGENATED POLYISOBUTENE • DIMETHICONE • GLYCERIN • BUTYROSPERMUM PARKII (SHEA) BUTTER • PANTHENOL • ALUMINUM STARCH OCTENYLSUCCINATE • BUTYLENE GLYCOL • PROPANEDIOL • CETYL PEG/PPG-10/1 DIMETHICONE • TRIHYDROXYSTEARIN • ZINC GLUCONATE • MADECASSOSIDE • MANGANESE GLUCONATE • SILICA • ALUMINUM HYDROXIDE • MAGNESIUM SULFATE • DISODIUM EDTA • COPPER GLUCONATE • CITRIC ACID • ACETYLATED GLYCOL STEARATE • POLYGLYCERYL-4 ISOSTEARATE • TOCOPHEROL • PENTAERYTHRITYL TETRA-DI-T-BUTYL HYDROXYHYDROCINNAMATE • SODIUM BENZOATE • PHENOXYETHANOL • CHLORHEXIDINE DIGLUCONATE TITANIUM DIOXIDE 

    Cicaplast Balm B5 is proven to help protect and relieve cracked, rough skin. This skin protectant immediately soothes dry irritated areas and provides comfort and hydration for dry to very dry skin. It is formulated with Vitamin B5 (Panthenol) and Madecassoside in an ultra-comforting, non-greasy texture. It also helps treat and prevent diaper rash

    $14.99 RRDi Affiliate Store
  21. Just to clarify, when a member doesn't post for 30 days, the active member is then automatically switched to the inactive member group. When an inactive member logs in and posts in any area open to guests, the member is automatically switched back to the active member group.
  22. Case Rep Dermatol. 2021 Jun 21;13(2):321-329. doi: 10.1159/000517209. eCollection 2021 May-Aug. ABSTRACT Lupus miliaris disseminatus faciei (LMDF) and granulomatous rosacea are 2 distinct inflammatory dermatoses with overlapping clinical features: reddish-yellow papular eruptions localized on the central face. Consequently, LMDF can easily be misdiagnosed as granulomatous rosacea or vice versa. Because delayed treatment in LMDF may increase chances of permanent scar formation, accurate diagnosis is important. We therefore analyzed published literature and case studies to organize the essential features differentiating LMDF from granulomatous rosacea. In addition, we report each case of LMDF and granulomatous rosacea for direct comparison. PMID:34248540 | PMC:PMC8255731 | DOI:10.1159/000517209 {url} = URL to article
  23. Front Immunol. 2021 Jun 24;12:698522. doi: 10.3389/fimmu.2021.698522. eCollection 2021. ABSTRACT Thymic stromal lymphopoietin (TSLP) was initially demonstrated to be critical in regulating inflammatory responses among various allergic disorders (such as atopic dermatitis, food allergy, and asthma). Although two isoforms (short form and long form) of TSLP have been demonstrated in human tissues, the long form of TSLP (lfTSLP) is strongly implicated in the pathogenesis of allergies and cutaneous immune-mediated diseases. The immunomodulatory activity of lfTSLP varies widely, driving T helper (Th) cells polarizing Th2 and Th17 immune responses and inducing itch. Moreover, lfTSLP is closely associated with skin fibrosis, epidermal hyperplasia, angiogenesis, and homeostatic tolerogenic regulations. This review highlights significant progress from experimental and clinical studies on lfTSLP in cutaneous immune-mediated diseases (atopic dermatitis, psoriasis, bullous pemphigoid, systemic sclerosis, chronic spontaneous urticaria, Behçet's disease, vitiligo, rosacea, systemic lupus erythematosus, and alopecia areata). We also offer original insights into the pleiotropic properties of the cytokine TSLP in various pathophysiological conditions, with significant clinical implications of TSLP-targeted therapies for immune-mediated skin diseases in the future. PMID:34249003 | PMC:PMC8264505 | DOI:10.3389/fimmu.2021.698522 {url} = URL to article
  24. A novel topical consisting of 15% Azelaic Acid and 1% Dihydro Avenanthramide D for rosacea is mentioned in a clinical paper posted in our member forum at this link. You will need to join the RRDi to view this post. Membership is free. We happen to have the MOST private rosacea forum on the internet, if you join using Sign in with Apple and use Apple's Hide My Email. Android users can still join as well as Windows users are welcome.
  25. An article published at mgblifestyle, discusses 'cold and formaldehyde-containing foods' as well as 'a pretty fancy-sounding protein' (actually a couple of fancy sounding proteins) that 'sets off a chain reaction that ultimately results in the release of histamines and cathelicidins by your skin's immune system.' The two proteins discussed in the article are transient receptor potential vanilloid 4 (TRPV4) and transient receptor potential alkyrin 1 (TRPA1). New Research Shows How Certain Foods & Drinks Affect Rosacea, Alexandra Engler, mgblifestyle Grapefruit image courtesy of Wikimedia Commons
  26. Received the 2019 Form 990 from the AARS. Total revenue received $258,366. Who contributed most of the revenue? The 'skin industry.' GALDERMA LABORATORIES L.P. $87.5K LA ROCHE POSAY $15K ORTHO DERMATOLOGICS $35K SOL-GEL TECHNOLOGIES INC. $15K SUN PHARMACEUTICALS $36K ALMIRALL, LLC (FORMERLY AQUA PHARMA) $35K BOTANIX PHARMACEUTICALS $5K EPI HEALTH, LLC $5K Total donations from the skin industry is $233.5K. The AARS was refunded one of the grants given out last year in the amount of $10K and also received $10,150 in membership dues from dermatologists. See below: What did the AARS spend most of its donations on? Again, the largest amount was on 'Conferences, conventions, and meetings' in the amount of $167,836. Two other large expenses was $48K on 'management' and $12,280 on 'website expenses.' See below: Is this the way you think a non profit organization for rosacea should be run? If you are a dermatologist it seems appropriate to run this non profit the way it is run. However, if you are a rosacea sufferer, is this the rosacea non profit organization you want to support? Why should there be a rosacea non profit run by rosaceans? You can read the Form 990 below: AARS-2020Form990.pdf
  27. Received the 2019 Form 990 from the AARS. Total revenue received $195,638 and here is the breakdown of the top contributors who donate at least $5K: ACLARIS THERAPEUTICS $10K CUTANEA LIFE SCIENCES (NOW OWNED BY BIOFRONTERA) $35K CASSIOPEA S.P.A. $10K FOAMIX PHARMACEUTICALS $10K GALDERMA LABORATORIES L.P. $50K RODAN AND FIELDS, LLC $35K THE PROACTIV COMPANY $35K Total from 'skin industry' $185K It would be safe to say that the vast majority of donations are from the 'skin industry.' In addition to this, $10,450.00 revenue came from membership dues (dermatologists). It would be prudent to note that there is little, if any, public support donations to the AARS. This organization operates more like a 501 6 c which is a business league. What did the AARS spend most of the 'donations' on? $234,961 on "Conferences, conventions, and meetings." You ask, how can the AARS spend more than it received in revenue? Answer: carry over assets. One expense worth noting is how the AARS spent $3,830.00 on its website. Here is a screen shot of all the expenses: The AARS did spend $40K on research grants in 2019 and you can review below who received the money: Your can read the form 990 yourself below: AARS-2019-Form990.pdf
  1. Load more activity


×
×
  • Create New...